Mda mb 231

For in vitro studies, we used three categories of breast cell lines. For Luminal A (LumA) phenotype we used T47D (from ICLC cell biobank, Genova, It), for luminal B (LumB) we used the BT474 (kindly provided by Dr. Daniela Gaglio, IBFM-CNR), for HER2+ phenotype we used SKBR3 (ATCC, Manassas, Virginia, USA), and lastly, for TNBC phenotype we used MDA-MB-231 (ICLC). These cell lines have been selected as representative of the BC subtypes, as reported in [31 (link)]. MCF-10 (ATCC) cell line was used as control, being representative of a non-tumorigenic epithelial cell line. T47D cells were cultured in High Glucose DMEM (Gibco, Life Technologies, Carlsbad, California, Stati Uniti); SKBR3 and BT-474 in RPMI (Euroclone, Italy) and MDA-MB-231 and MCF-10 in Advanced DMEM (Euroclone, Italy). All of the media were supplemented with 10% heat-inactivated foetal bovine serum, penicillin and streptomycin (50 IU/mL), and 2 mM glutamine (all Euroclone, Italy). The cells were maintained in a humidified atmosphere of 5% CO₂ at 37 °C.

Human acute T leukemia (Jurkat), human epidermoid carcinoma (A-431), estrogen (ER) and progesterone (PR) receptor-positive human breast cancer (MCF-7), and ER, PR, and epidermal growth factor receptor-2 (HER2)-negative human breast cancer (MDA-MB-231) cells were obtained from LGC Standard (LGC Group, Middlesex, UK).
Jurkat, A-431, and MDA-MB-231 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium, supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% L-glutamine 200 mM, and 1% penicillin (10,000 units)/streptomycin (10 mg/mL) solution (all provided by Euroclone, Pero, Italy). MCF-7 cells were propagated in Dulbecco’s modified Eagle’s medium (DMEM, Euroclone) supplemented with 10% FBS, 1% L-glutamine 200 mM, 1% penicillin/streptomycin, and 0.1% insulin. All cells were maintained at 37 °C under 5% CO₂ in a humidified incubator.

For in vitro studies, we used three categories of breast cell lines. For Luminal A (LumA) phenotype we used T47D (from ICLC cell biobank, Genova, It), for luminal B (LumB) we used the BT474 (kindly provided by Dr. Daniela Gaglio, IBFM-CNR), for HER2+ phenotype we used SKBR3 (ATCC, Manassas, Virginia, USA), and lastly, for TNBC phenotype we used MDA-MB-231 (ICLC). These cell lines have been selected as representative of the BC subtypes, as reported in [31 (link)]. MCF-10 (ATCC) cell line was used as control, being representative of a non-tumorigenic epithelial cell line. T47D cells were cultured in High Glucose DMEM (Gibco, Life Technologies, Carlsbad, California, Stati Uniti); SKBR3 and BT-474 in RPMI (Euroclone, Italy) and MDA-MB-231 and MCF-10 in Advanced DMEM (Euroclone, Italy). All of the media were supplemented with 10% heat-inactivated foetal bovine serum, penicillin and streptomycin (50 IU/mL), and 2 mM glutamine (all Euroclone, Italy). The cells were maintained in a humidified atmosphere of 5% CO₂ at 37 °C.